GlobalData on MSN

Excellergy eyes IgE therapy space as Xolair nears patent expiry

Zavodnick told Pharmaceutical Technology that Excellergy plans to initiate an ex-US Phase I study of its lead ECRI candidate, a monoclonal antibody, in Q1 2026, with the goal of being ready for Phase ...

Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program

The research is supported by the National Institute of Allergy and Infectious Diseases of the NIH under award number ...

Is it cheaper to pay for medical care without health insurance?

Hospitals or clinics may offer cash-only discounts to people who pay without insurance. But experts warn that health care isn ...
Medscape

Man Develops Antibiomania After Antibiotic Therapy

A 66-year-old man develops acute mania after antibiotic therapy for a urinary infection, highlighting a rare but serious ...

Cushing’s Disease in Dogs: Understanding the Signs, Causes, and Treatments

From the "pot-bellied" appearance to the flaws in the LDDST, Cushing's disease remains one of our most complex endocrine ...
Crescent-NewsOpinion

Michael Roizen, M.D.: Making the most of retirement; the obesity-Alzheimer's connection

Q: I’m slated to retire next year, and it scares me to death — well, I hope not death, exactly, but I’m not sure what to do ...
TipRanks on MSN

Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment

Ars Pharmaceuticals, Inc. (($SPRY)) announced an update on their ongoing clinical study. Study Overview: Ars Pharmaceuticals, Inc. is conducting a ...
The Malaysian Reserve

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years

Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies TREMFYA® is the only ...